AstraZeneca partners with Quell Therapeutics for cell therapies in autoimmune diseases.
TL;DR Summary
AstraZeneca has partnered with Quell Therapeutics to develop regulatory T cell therapies for type 1 diabetes and inflammatory bowel disease. As part of the deal, AstraZeneca will pay Quell $85m upfront, with a potential $2bn in downstream milestones, plus royalties. Quell will manufacture the therapies until the end of the first clinical trials, after which AstraZeneca has the option to license, develop and commercialize the treatments.
Topics:business#astrazeneca#healthcare#inflammatory-bowel-disease#quell-therapeutics#regulatory-t-cell-therapies#type-1-diabetes
- AstraZeneca dives into regulatory T cell therapies in deal with Quell Therapeutics Endpoints News
- AstraZeneca pays $85M to Quell Type 1 diabetes with 'one and done' cell therapy FierceBiotech
- AstraZeneca signs $2 billion agreement with Quell to develop cell therapies Reuters
- Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases GlobeNewswire
- Astra Enters Into $2 Billion-Plus Pact With UK Biotech Quell Bloomberg
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
0 min
vs 1 min read
Condensed
50%
133 → 66 words
Want the full story? Read the original article
Read on Endpoints News